.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Cantor Fitzgerald
Covington
McKesson
US Army
Colorcon
Harvard Business School
Medtronic
Chubb
US Department of Justice

Generated: September 24, 2017

DrugPatentWatch Database Preview

Genzyme Corp Company Profile

« Back to Dashboard

What is the competitive landscape for GENZYME CORP, and when can generic versions of GENZYME CORP drugs launch?

GENZYME CORP has five approved drugs.

There are five US patents protecting GENZYME CORP drugs.

There are one hundred and thirteen patent family members on GENZYME CORP drugs in thirty-nine countries.

Summary for Applicant: Genzyme Corp

Patents:5
Tradenames:4
Ingredients:4
NDAs:5
Drug Master File Entries: (click here to view)5
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genzyme Corp
HECTOROL
doxercalciferol
CAPSULE;ORAL020862-002Apr 23, 2004ABRXYesNo► Subscribe► Subscribe► Subscribe
Genzyme Corp
HECTOROL
doxercalciferol
INJECTABLE;INJECTION021027-001Apr 6, 2000APRXYesYes► Subscribe► Subscribe► Subscribe
Genzyme Corp
CERDELGA
eliglustat tartrate
CAPSULE;ORAL205494-001Aug 19, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Genzyme Corp
CAPRELSA
vandetanib
TABLET;ORAL022405-001Apr 6, 2011RXYesNo► Subscribe► SubscribeY ► Subscribe
Genzyme Corp
CAPRELSA
vandetanib
TABLET;ORAL022405-002Apr 6, 2011RXYesYes► Subscribe► SubscribeYY ► Subscribe
Genzyme Corp
HECTOROL
doxercalciferol
CAPSULE;ORAL020862-001Jun 9, 1999ABRXYesYes► Subscribe► Subscribe► Subscribe
Genzyme Corp
CAPRELSA
vandetanib
TABLET;ORAL022405-001Apr 6, 2011RXYesNo► Subscribe► Subscribe► Subscribe
Genzyme Corp
CERDELGA
eliglustat tartrate
CAPSULE;ORAL205494-001Aug 19, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Genzyme Corp
HECTOROL
doxercalciferol
CAPSULE;ORAL020862-003Jul 13, 2009ABRXYesNo► Subscribe► Subscribe► Subscribe
Genzyme Corp
CAPRELSA
vandetanib
TABLET;ORAL022405-002Apr 6, 2011RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Genzyme Corp

Paragraph IV activity for GENZYME CORP drugs

Drugname Dosage Strength Tradename Submissiondate
doxercalciferol
Injection2 mcg/mL, 1 mL in 2 mL vial
HECTOROL
12/28/2011
doxercalciferol
Capsules1 mcg
HECTOROL
2/12/2010
doxercalciferol
Capsules0.5 mcg and 2.5 mcg
HECTOROL
3/25/2009
doxercalciferol
Injection2 mcg/mL, 2 mL ampules
HECTOROL
10/15/2007

Non-Orange Book Patents for Genzyme Corp

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,855,830 Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors► Subscribe
7,265,228Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors► Subscribe
9,546,161Synthesis of UDP-glucose: N-acylsphingosine glucosyl transferase inhibitors► Subscribe
5,916,911 Amino ceramide--like compounds and therapeutic methods of use► Subscribe
6,040,332 Amino ceramide-like compounds and therapeutic methods of use► Subscribe
6,414,148 Quinazoline derivatives and pharmaceutical compositions containing them► Subscribe
6,030,995 Amino ceramide-like compounds and therapeutic methods of use► Subscribe
7,763,738Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors► Subscribe
5,952,370 Amino ceramide-like compounds and therapeutic methods of use► Subscribe
8,779,163Synthesis of UDP-Glucose: N-acylsphingosine glucosyl transferase inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Genzyme Corp Drugs

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)9813354► Subscribe
Israel159905► Subscribe
World Intellectual Property Organization (WIPO)0104108► Subscribe
Poland190326► Subscribe
BrazilPI0511253► Subscribe
Hungary9902850► Subscribe
Austria439841► Subscribe
Spain2395463► Subscribe
Japan2015180656► Subscribe
European Patent Office1753431► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Genzyme Corp Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
717Luxembourg► SubscribePRODUCT NAME: ELIGLUSTAT, EVENTUELLEMENT SOUS LA FORME D UN SEL PHYSIOLOGIQUEMENT ACCEPTABLE. FIRST REGISTRATION: 20150121
00738Netherlands► SubscribePRODUCT NAME: ELIGLUSTAT, OF FYSIOLOGISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/14/974 20150119
0543Netherlands► SubscribePRODUCT NAME: VANDETANIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/11/749/001-002 20120217
/2015Austria► SubscribePRODUCT NAME: ELIGLUSTAT, OPTIONAL IN DER FORM EINES PHYSIOLOGISCH AKZEPTABLEN SALZES; REGISTRATION NO/DATE: EU/1/14/974 20150119
2012015Lithuania► SubscribePRODUCT NAME: VANDETANIBUM; REGISTRATION NO/DATE: EU/1/11/749/001, 2012 02 17 EU/1/11/749/002 20120217
90028-8Sweden► SubscribePRODUCT NAME: VANDETANIB ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV; REG. NO/DATE: EU/1/11/749/001 20120217
90029-3Sweden► SubscribePRODUCT NAME: ELIGLUSTAT, VALFRITT I FORM AV ETT FYSIOLOGISKT GODTAGBART SALT; REG. NO/DATE: EU/1/14/974 20150121
12/029Ireland► SubscribePRODUCT NAME: VANDETANIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/11/749/001-002 20120217
C0036France► SubscribePRODUCT NAME: ELIGLUSTAT,EVENTUELLEMENT SOUS FORME D'UN SEL PHYSIOLOGIQUEMENT ACCEPTABLE; REGISTRATION NO/DATE: EU/1/14/974 20150119
0150027 00161Estonia► SubscribePRODUCT NAME: ELIGLUSTAAT;REG NO/DATE: EU/1/14/974 21.01.2015
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Baxter
Boehringer Ingelheim
McKesson
UBS
Chubb
Fish and Richardson
Moodys
Argus Health
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot